Abstract
Background/objectives:
Vitamin D has anti-inflammatory and immune-regulating properties. We aimed to determine if high-dose cholecalciferol supplementation for 1 year in subjects with early chronic kidney disease (CKD) improved circulating markers of inflammation and immunity.
Subjects/methods:
In this double-blind, randomized, placebo-controlled trial, 46 subjects with early CKD (stages 2 and 3) were supplemented with oral cholecalciferol (50 000 IU weekly for 12 weeks followed by 50 000 IU every other week for 40 weeks) or a matching placebo for 1 year. Serum tumor necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1 (MCP-1), interferon gamma-induced protein-10 and neutrophil gelatinase-associated lipocalin were measured at baseline, 12 weeks and 1 year. Serum cathelicidin (LL-37) was measured at baseline and 12 weeks. An in vitro experiment was performed to investigate the effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment on MCP-1 secretion in THP-1 monocytes activated with lipopolysaccharide (LPS) and Pseudomonas aeruginosa.
Results:
By 12 weeks, serum MCP-1 decreased in the cholecalciferol group (66.2±2.5 to 60.8±2.6 pg/ml, group-by-time interaction P=0.02) but was not different from baseline at 1 year. Other markers of inflammation and immunity did not change. In vitro, LPS- and Pseudomonas-activated monocytes treated with 1,25(OH)2D3 had significantly less MCP-1 secretion compared with untreated cells.
Conclusions:
High-dose cholecalciferol decreased serum MCP-1 concentrations by 12 weeks in patients with early CKD, although the decrease was not maintained for the remainder of the year. In vitro results confirm an MCP-1-lowering effect of vitamin D. Future studies should determine if vitamin D-mediated reductions in MCP-1 concentrations reflect improved clinical outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1–201.
Judd SE, Tangpricha V . Vitamin D therapy and cardiovascular health. Curr Hypertens Rep 2011; 13: 187–191.
Stinghen AE, Bucharles S, Riella MC, Pecoits-Filho R . Immune mechanisms involved in cardiovascular complications of chronic kidney disease. Blood Purif 2010; 29: 114–120.
Sterling KA, Eftekhari P, Girndt M, Kimmel PL, Raj DS . The immunoregulatory function of vitamin D: implications in chronic kidney disease. Nat Rev Nephrol 2012; 8: 403–412.
Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42: 1050–1065.
Wang HE, Gamboa C, Warnock DG, Muntner P . Chronic kidney disease and risk of death from infection. Am J Nephrol 2011; 34: 330–336.
Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK, Riches DW et al. Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol 2012; 188: 2127–2135.
Equils O, Naiki Y, Shapiro AM, Michelsen K, Lu D, Adams J et al. 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol 2006; 143: 58–64.
Kamen DL, Tangpricha V . Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) 2010; 88: 441–450.
Wang TT, Nestel FP, Bourdeau V, Nagai Y, Wang Q, Liao J et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004; 173: 2909–2912.
Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S . Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58: 374–382.
Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31: 2253–2261.
Naves-Díaz M, Álvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070–1078.
Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, Shahid Salles K et al. High-dose cholecalciferol reduces parathryroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2012; 96: 672–679.
Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247–254.
Zughaier SM, Tzeng YL, Zimmer SM, Datta A, Carlson RW, Stephens DS . Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun 2004; 72: 371–380.
Zughaier SM, Zimmer SM, Datta A, Carlson RW, Stephens DS . Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect Immun 2005; 73: 2940–2950.
Kang YS, Cha JJ, Hyun YY, Cha DR . Novel C-C chemokine receptor 2 antagonists in metabolic disease: a review of recent developments. Expert Opin Investig Drugs 2011; 20: 745–756.
Tesch GH . MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008; 294: F697–F701.
de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690–695.
Yadav A, Saini V, Arora S . MCP-1: chemoattractant with a role beyond immunity: a review. Clin Chim Acta 2010; 411: 1570–1579.
Gao D, Trayhurn P, Bing C . 1,25-Dihydroxyvitamin D3 inhibits the cytokine-induced secretion of MCP-1 and reduces monocyte recruitment by human preadipocytes. Int J Obes (Lond) 2012 e-pub ahead of print 17 April 2012; doi:10.1038/ijo.2012.53.
Lorente-Cebrián S, Eriksson A, Dunlop T, Mejhert N, Dahlman I, Åström G et al. Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr 2012; 51: 335–342.
Gruber HE, Hoelscher G, Ingram JA, Chow Y, Loeffler B, Hanley EN . 1,25(OH)2-vitamin D3 inhibits proliferation and decreases production of monocyte chemoattractant protein-1, thrombopoietin, VEGF, and angiogenin by human annulus cells in vitro. Spine (Phila Pa 1976) 2008; 33: 755–765.
Zhang Z, Yuan W, Sun L, Szeto FL, Wong KE, Li X et al. 1,25-Dihydroxyvitamin D3 targeting of NF-κB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007; 72: 193–201.
Zhu KJ, Shen QY, Zheng M, Mrowietz U . Effects of calcitriol and its analogues on interaction of MCP-1 and monocyte derived dendritic cells in vitro. Acta Pharmacol Sin 2001; 22: 62–65.
Krüger S, Kreft B . 1,25-Dihydroxyvitamin D3 differentially regulates IL-1α-stimulated IL-8 and MCP-1 mRNA expression and chemokine secretion by human primary proximal tubular epithelial cells. Exp Nephrol 2001; 9: 223–228.
Bischoff-Ferrari HA, Dawson-Hughes B, Stöcklin E, Sidelnikov E, Willett WC, Orav EJ et al. Oral supplementation with 25(OH)D3 versus vitamin D3: effects on 25(OH)D levels, lower extremity function, blood pressure and markers of innate immunity. J Bone Miner Res 2011; 27: 160–169.
Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD et al. Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 2011; 80: 851–860.
Jorde R, Sneve M, Torjesen PA, Figenschau Y, Gøransson LG, Omdal R . No effect of supplementation with cholecalciferol on cytokines and markers of inflammation in overweight and obese subjects. Cytokine 2010; 50: 175–180.
Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD . Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21: 353–361.
Bucharles S, Barberato SH, Stinghen AE, Gruber B, Piekala L, Dambiski AC et al. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. J Ren Nutr 2012; 22: 284–291.
Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5: 905–911.
McNally P, Coughlan C, Bergsson G, Doyle M, Taggart C, Adorini L et al. Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis. J Cyst Fibros 2011; 10: 428–434.
Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S et al. Vitamin D is required for IFN-γ-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011; 3: 104ra102.
Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770–1773.
Coussens AK, Wilkinson RJ, Hanifa Y, Nikolayevskyy V, Elkington PT, Islam K et al. Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc Natl Acad Sci USA 2012; 109: 15449–15454.
Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP et al. High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242–250.
Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H . Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010; 91: 1255–1260.
Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V . Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009; 15: 438–449.
Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC et al. Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 2012; 308: 1333–1339.
Soni SS, Cruz D, Bobek I, Chionh CY, Nalesso F, Lentini P et al. NGAL: a biomarker of acute kidney injury and other systemic conditions. Int Urol Nephrol 2010; 42: 141–150.
Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009; 7: 28.
Rudnicki M, Kerschbaum J, Hausdorfer J, Mayer G, König P . Risk factors for peritoneal dialysis-associated peritonitis: the role of oral active vitamin D. Perit Dial Int 2010; 30: 541–548.
Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF et al. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 2009; 182: 4289–4295.
Acknowledgements
We thank Breanne Wright, Shabnan Seydafkan, Meena Kumari, Lynn Schlanger and Peggy Jenkins for their research coordinating support, and we thank Sarthak Khare for his assistance in sample preparation. Sources of support for this study include grants from the National Institutes of Health (K23AR054334 (VT), T32DK007298-32S1 (JAA), UL1 RR025008 (TRZ, VT) and K24 RR023356 (TRZ)), the Atlanta Research and Education Foundation (VT) and the Emory-Egleston Children’s Research Center (SMZ).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Alvarez, J., Zughaier, S., Law, J. et al. Effects of high-dose cholecalciferol on serum markers of inflammation and immunity in patients with early chronic kidney disease. Eur J Clin Nutr 67, 264–269 (2013). https://doi.org/10.1038/ejcn.2012.217
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejcn.2012.217
Keywords
This article is cited by
-
Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines
Calcified Tissue International (2021)
-
The effect of a single, large bolus of vitamin D in healthy adults over the winter and following year: a randomized, double-blind, placebo-controlled trial
European Journal of Clinical Nutrition (2015)
-
Vitamin D and the Cardiovascular System: An Overview of the Recent Literature
American Journal of Cardiovascular Drugs (2014)
-
The role of vitamin D deficiency in cardiovascular disease: where do we stand in 2013?
Archives of Toxicology (2013)